Cormedix Inc (CRMD) valuation
Cormedix P/E ratio history
Cormedix trades at 2.6 times its earnings over the last twelve months and 20.6 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $11.63 | $2.04 | 5.7 | 4.5 |
| Dec 31, 2024 | $8.10 | -$0.30 | n/m | — |
| Dec 31, 2023 | $3.76 | -$0.91 | n/m | — |
| Dec 31, 2022 | $4.22 | -$0.74 | n/m | — |
| Dec 31, 2021 | $4.55 | -$0.75 | n/m | — |
| Dec 31, 2020 | $7.43 | -$0.76 | n/m | — |
| Dec 31, 2019 | $7.28 | -$1.78 | n/m | — |
| Dec 31, 2018 | $6.45 | -$1.52 | n/m | — |
| Dec 31, 2017 | $2.50 | -$3.10 | n/m | — |
| Dec 31, 2016 | $7.65 | -$3.15 | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Cormedix valuation against its peers
| Company | Market value | Forward P/E | Price / sales |
|---|---|---|---|
| CormedixCRMD | $447M | 20.6 | 1.0 |
| Prothena PlcPRTA | $443M | — | 8.1 |
| Gyre TherapeuticsGYRE | $442M | — | 3.7 |
| CerusCERS | $457M | — | 1.8 |
| NeurogeneNGNE | $435M | — | — |
| Phathom PharmaceuticalsPHAT | $464M | 7.2 | 1.7 |
| Monopar TherapeuticsMNPR | $471M | — | — |
| NeuropaceNPCE | $419M | — | 4.2 |
| Avita MedicalRCEL | $482M | — | 6.4 |
| Peer median | 7.2 | 4.0 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: CRMD financials · CRMD returns
No forecast, no recommendation. This page describes Cormedix Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.